Although the regulation mechanism of this enzyme has been understood, deficiency of NPP1 has been associated with arterial calcification of infancy in humans and calcium phosphate deposition in the joints and spine of murine models [11]. NPP1 has been explored as a potential therapeutic target for CPPD, diabetes, and cancer. The gene discussed is ENPP1; the disease is cancer.